biosimilaradj.n.

Brit.

/ˌbʌɪəʊˈsɪm(ᵻ)lə/, U.S.

/ˌbaɪoʊˈsɪm(ə)lər/

Origin: Formed within English, by compounding. Etymons: bio- comb. form, similar adj.

Etymology: < bio- comb. form + similar adj.

Medicine.

A. adj.

Of a biopharmaceutical, esp. one produced by recombinant DNA technology: designed to have active properties similar to those of a previously licensed biopharmaceutical. Cf. biogeneric adj.

ΘΚΠ

the world > health and disease > healing > medicines or physic > [adjective] > other qualities of medicines

lighteOE

emphractic1659

concentrant1721

potentized1851

antiperiodic1861

weak1899

stathmokinetic1939

bioavailable1973

biosimilar2002

2002 European Drug Rep. 4 Nov. 2/2 Biosimilar products—those having the same physico-chemical and biological properties and pharmaceutical form as the brand drug.

2009 H. Schellekens in S. G. Elliott et al. Erythropoietins, Erythropoietic Factors, & Erythropoiesis (ed. 2) 111 Alpheon, a biosimilar version of Roferon-A (IFN alfa-2a), was rejected by the EMEA.

2011 N.Y. Times (Nexis) 20 Dec. b6 Amgen has plans for other biosimilar drugs.

B. n.

A biosimilar drug. Cf. biogeneric n.

ΚΠ

2003 Pharma Marketletter (Nexis) 6 Oct. To be approved, ‘biosimilars’ must undergo a re-clinical testing and clinical trials procedure which is different from..generic versions of chemical drugs.

2013 M. Osmane Rift-lines European Regulatory Framework for Biosimilars vi. 210 The biosimilar..must show independent safety for patients by clinical trials.

This is a new entry (OED Third Edition, June 2014; most recently modified version published online December 2021).

单词	biosimilar
释义	biosimilaradj.n. Brit. /ˌbʌɪəʊˈsɪm(ᵻ)lə/, U.S. /ˌbaɪoʊˈsɪm(ə)lər/ Origin: Formed within English, by compounding. Etymons: bio- comb. form, similar adj. Etymology: < bio- comb. form + similar adj. Medicine. A. adj. Of a biopharmaceutical, esp. one produced by recombinant DNA technology: designed to have active properties similar to those of a previously licensed biopharmaceutical. Cf. biogeneric adj. ΘΚΠ the world > health and disease > healing > medicines or physic > [adjective] > other qualities of medicines lighteOE emphractic1659 concentrant1721 potentized1851 antiperiodic1861 weak1899 stathmokinetic1939 bioavailable1973 biosimilar2002 2002 European Drug Rep. 4 Nov. 2/2 Biosimilar products—those having the same physico-chemical and biological properties and pharmaceutical form as the brand drug. 2009 H. Schellekens in S. G. Elliott et al. Erythropoietins, Erythropoietic Factors, & Erythropoiesis (ed. 2) 111 Alpheon, a biosimilar version of Roferon-A (IFN alfa-2a), was rejected by the EMEA. 2011 N.Y. Times (Nexis) 20 Dec. b6 Amgen has plans for other biosimilar drugs. B. n. A biosimilar drug. Cf. biogeneric n. ΚΠ 2003 Pharma Marketletter (Nexis) 6 Oct. To be approved, ‘biosimilars’ must undergo a re-clinical testing and clinical trials procedure which is different from..generic versions of chemical drugs. 2013 M. Osmane Rift-lines European Regulatory Framework for Biosimilars vi. 210 The biosimilar..must show independent safety for patients by clinical trials. This is a new entry (OED Third Edition, June 2014; most recently modified version published online December 2021). < adj.n.2002
随便看	put up big numbers put up etc numbers put up good numbers put up numbers put up one's appearance put up one's pipes put up one's sleeve put up or shut up put up the banns put up the game put up the pole put up the shutters put up the spout put up to her mettle put up to his mettle put up to market put up to sale put up to the hammer put up with put up, turn up hair put up, turn up one's hair put upon put upon an issue put upon her mettle put upon his mettle